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Evaluation of the role of clinical pharmacist in optimizing the
use of stress ulcer prophylaxis and thromboembolic events
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Background: Every patient admifted to hospital may be at risk of stress related mi- -, '
disease (SRMD) and venous thromboembolic events (VTE). Therefore, it is neces'''::-
to evaluate each patient regarding the risk of SRIT4D and VTE. Patients with imp":.:
renal function are at increased risk of bleeding. So they may receive exces=-'' =
inappropriate regimens for prophylaxis of SRMD while the rate of approp:--':'
prescription for VTE prophylaxis may be less than that of other patients. As a res'*--
clinical phannacists can effectively improve the rate of prescription of prophl'1ac-r-
regimens in this group of patients. Therefore, this study was designed to evaluate i:.
role of clinical pharmacist interventions in optimizing the use of SRMD prophf ia'-.
and VTE prophylaxis in a nephrology ward.
Methods: This trial was a cross-sectional and interventional study conducted ir .
nephrology ward of a teaching hospital. This was a pre and post interventional stui'"
Patients that were admitted in this ward over the period of the study and had hospi---
stay of more than 24 hours were considered for inclusion. Patients who were reeeir r:':
acid suppressive therapy (AST) because of GI diseases or GI complaints and Patie:-
aged more than 65 years receiving ASA+ clopidogrel and those with GI bleeding drir::-;
the study were excluded from the evaluation of SRMD risk. Also patients who u'e:=
receiving therapeutic doses of anticoagulants prior to admission and during the st*:"
were excluded from the evaluation of VTE risk. In the three-month pre inten'ent: ::
study, investigators evaluated physician's practice of SRMD and VTE prophylais. -
the next three-month interventional phase, pharmacy student and a clinical pharrr'"::r
actively participated in daily visits of patients and recommended the clinicianS r--l - :
appropriateness of prescribing AST and anticoagulants as SRMD and DVT prophl -,-.-',
respectively. The American society of health system pharmacists (ASHP) thera;'- ---':
guidelines on stress ulcer prophylaxis was used to evaluate patients regarding the :-.., - '
SRMD. Caprini risk score and modified Padua risk assessment model rn'as '*';: '
evaluate patients regarding the risk of VTE.
IV u*)k\ * -''-
Results:
SRMD prophylaxis evaluation: fifty seven and 44 patients were evaluated in the pre a: :
post intervention phases, respectively. The rate of AST was reduced from 84.21% in r.
pre intervention phase to 43.1 8% (P<0.001) in the post inten'ention phase.
VTE prophylaxis er.aluation: Sixty four and 59 patients were evaluated in the pre a::
post intenention phases, respectively. The rate of VTE prophylaxis prescription \\'2-.
increased from 3I.25% in the pre intervention phase to 50.84o/o (P:0.02) in the pos.
intervention phase.
Discussion: Clinical pharmacist intervention significantly decreased the rate c
inappropriate and increased the rate of appropriate prescriptions for prophylaiis c:
SRMD and VTE.
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